$LIVN (LivaNova PLC)

$LIVN {{ '2016-07-29T05:44:54+0000' | timeago}} • Announcement

$LIVN said it received Canadian regulatory approval for its Memo 3D ReChord, a semirigid prosthetic annuloplasty ring for Mitral Valve Repair (MVR). MVR is an option, rather than mitral valve replacement, that can provide patients with improved heart function and preservation of lifestyle.

$LIVN {{ '2018-01-11T17:37:05+0000' | timeago}} • Announcement

$LIVN said the first patient has been enrolled in the Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-Surgical Aortic Valve Implant Study. The study is expected to enroll about 230 patients at 15 sites from the U.S. and Canada to ascertain whether valve leaflets are fully operational following surgery.

$LIVN {{ '2018-01-08T14:58:25+0000' | timeago}} • Announcement

$LIVN announced Matthew J. Dodds has joined the company as SVP, Corporate Development. In this role, Dodds is responsible for Business Development, Investor Relations and Corporate Communications.

$LIVN {{ '2017-12-05T14:44:32+0000' | timeago}} • Announcement

$LIVN has agreed to acquire the remaining outstanding interests in ImThera Medical, Inc. for approx. $225MM. Up-front costs are approx. $78MM with the balance paid on a schedule driven by regulatory and sales milestones. The deal is projected to be near-term accretive and is expected to close in early 2018.

$LIVN {{ '2017-11-20T12:54:20+0000' | timeago}} • Announcement

$LIVN and MicroPort Scientific Corporation have entered into a binding Letter of Intent for the sale of LivaNova’s Cardiac Rhythm Management Business Franchise to MicroPort for $190MM in cash. The companies expect the transaction to close in the second quarter of 2018.

$LIVN {{ '2017-10-09T12:48:05+0000' | timeago}} • Announcement

$LIVN said it has received US FDA approvals for its latest Vagus Nerve Stimulation Therapy System, which consists of the SenTiva implantable generator and the next-generation VNS Therapy Programming System for the treatment of patients with drug-resistant epilepsy.

$LIVN {{ '2017-09-27T16:43:35+0000' | timeago}} • Announcement

$LIVN and MicroPort Scientific Corp. said that the companies' Shanghai-based joint venture MicroPort Sorin Cardiac Rhythm Management obtained approval for its family of Rega pacemakers from the China Food and Drug Administration. Rega pacemakers are the smallest on the Chinese cardiac rhythm management market.

$LIVN {{ '2017-09-25T16:00:14+0000' | timeago}} • Announcement

$LIVN got FDA 510(k) clearance for the US market launch of its Optiflow Arterial Cannulae family. Optiflow aortic arch cannulae provide improved hydrodynamics with a novel dispersive tip design that improves blood flow characteristics resulting in reduced wall shear stress profiles and thereby reducing complications during cardiac surgery.

$LIVN {{ '2017-09-14T20:47:42+0000' | timeago}} • Announcement

$LIVN intends to invest in inorganic opportunities within adjacent and underserved markets. The company expects to achieve revenue growth in the mid-single-digits in the near term and high-single-digits in the long term. $LIVN anticipates compounded annual earnings per share growth in the low- to mid-teens from 2017 to 2022.

$LIVN {{ '2017-08-04T17:57:58+0000' | timeago}} • Announcement

Medical technology company $LIVN said its sutureless aortic heart valve Perceval was approved by the Centers for Medicare and Medicaid Services (CMS) for a New Technology Add-on Payment. CMS will reimburse hospitals for the Perceval valve procedure, starting October 1, 2017. The Perceval valve optimizes the surgical procedure.

$LIVN {{ '2017-07-12T12:45:32+0000' | timeago}} • Announcement

$LIVN appointed Keyna Skeffington as SVP and General Counsel. Skeffington most recently served as Vice President of Legal – Corporate and Securities, Deputy General Counsel and Assistant Secretary at $MDT.

$LIVN {{ '2017-06-29T15:56:55+0000' | timeago}} • Announcement

$LIVN received FDA approval of its VNS Therapy system in patients as young as four years of age with partial onset seizures that are refractory to antiepileptic medications.

$LIVN {{ '2017-06-21T14:06:24+0000' | timeago}} • Announcement

$LIVN said its latest VNS Therapy systems received FDA approval for expanded MRI labeling, affirming VNS Therapy as the only epilepsy device approved by the FDA for MRI scans. This ensures VNS patients with latest technology may visit any MRI center in US and have access to more than 90% of scans routinely performed on patients with epilepsy.

$LIVN {{ '2017-06-12T14:07:22+0000' | timeago}} • Announcement

$LIVN announced the appointment of Keyna Skeffington as SVP and General Counsel. She most recently served as VP of Legal – Corporate and Securities, Deputy General Counsel and Assistant Secretary at Medtronic PLC.

$LIVN {{ '2017-05-16T13:32:11+0000' | timeago}} • Announcement

$LIVN appointed Thad Huston as its new CFO, effective May 20, 2017. The company's former CFO Vivid Sehgal is coordinating with Huston to ensure an orderly transition. Huston will report directly to CEO Damien McDonald. Most recently, Huston served as Group CFO, Medical Devices at $JNJ.

$LIVN {{ '2017-05-03T12:53:24+0000' | timeago}} • Announcement

As a result of the Caisson Interventional acquisition, $LIVN expects to recognize a pretax non-cash gain during 2Q17 on the $15MM book value of its existing investment in Caisson. The acquisition will be dilutive to earnings for several years. The 2017 guidance will be updated to include the estimated impact of the acquisition.

$LIVN {{ '2017-05-03T12:53:08+0000' | timeago}} • Announcement

$LIVN acquired the remaining outstanding interests in Caisson Interventional, LLC. $LIVN agreed to pay up to $72MM, net of $6MM of debt forgiveness, to acquire the remaining 51% of the company. The first payment of $18MM was made at closing with the balance paid on a schedule driven primarily by regulatory approvals and sales earn-outs.

$LIVN {{ '2017-03-31T14:05:29+0000' | timeago}} • Announcement

Medical technology and innovation company $LIVN announced that its CFO, Vivid Sehgal, is leaving the company to pursue other opportunities. Sehgal will continue as CFO and will support an orderly transition to his successor while the company is underway with an external search to identify a replacement.

$LIVN {{ '2016-09-22T14:41:05+0000' | timeago}} • Announcement

Maker of medical devices $LIVN unveiled PLATINIUM, its new range of implantable cardiac defibrillators (ICDs) & cardiac resynchronization therapy devices (CRT-Ds). These models offer longevity of devices with service life projected to last over 14 years for single-chamber ICD, over 13 years for dual-chamber ICD and over 10 years for CRT-D devices.

$LIVN {{ '2016-08-29T11:26:56+0000' | timeago}} • Announcement

$LIVN announced long term results from the RESPOND-CRT clinical trial after an 18 month follow-up period. The trial was designed to investigate the clinical efficacy and safety of device-based optimization using $LIVN's proprietary SonR cardiac contractility sensor technology in patients with advanced heart failure.

$LIVN {{ '2016-08-01T13:58:08+0000' | timeago}} • Announcement

$LIVN said it appointed Damien McDonald as its new Chief Operating Officer (COO), effective Oct. 3, 2016. McDonald will report to CEO Andre-Michel Ballester as a member of its executive team and will be domiciled in London. The transition to its new realigned organization is expected to be completed by the end of 2016.

Recent Transcripts

INFO (IHS Markit Ltd.)
Tuesday, January 16 2018 - 1:00pm
HQY (HealthEquity, Inc.)
Tuesday, December 5 2017 - 10:00pm
MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
VVV (Valvoline Inc.)
Thursday, November 9 2017 - 2:00pm
AJX (Great Ajax Corp)
Tuesday, November 7 2017 - 10:00pm
APPS (Digital Turbine, Inc.)
Tuesday, November 7 2017 - 9:30pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
BHF (Brighthouse Financial, Inc.)
Thursday, November 2 2017 - 4:00pm
LIVN (LivaNova PLC)
Thursday, November 2 2017 - 1:00pm
RTIX (RTI Surgical Inc.)
Thursday, November 2 2017 - 12:30pm
DWDP (DowDuPont Inc.)
Thursday, November 2 2017 - 12:00pm
TFX (Teleflex Incorporated)
Thursday, November 2 2017 - 12:00pm
FIT (Fitbit Inc.)
Wednesday, November 1 2017 - 9:00pm
WMGI (Wright Medical Group N.V.)
Wednesday, November 1 2017 - 8:30pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
OFIX (Orthofix International N.V.)
Monday, October 30 2017 - 8:30pm
NUVA (NuVasive, Inc.)
Tuesday, October 24 2017 - 8:30pm
ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm
INFO (IHS Markit Ltd.)
Tuesday, September 26 2017 - 12:00pm

AlphaGraphics you may like